Prospective Comparison of [18F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography in Patients With Melanoma With Palpable Lymph Node Metastases: Diagnostic Accuracy and Impact on Treatment
Authors:
- Theo WobbesTWTheo Wobbes
- Otto S. HoekstraOHOtto S. Hoekstra
- Eric J. van der JagtEJEric J. van der Jagt
- Adrienne H. BrouwersABAdrienne H. Brouwers
- Ron KoelemijRKRon Koelemij
- John M.H. de KlerkJKJohn M.H. de Klerk
- Wim J.G. OyenWim J.G. Oyen
- Sybren MeijerSMSybren Meijer
- Harald J. HoekstraHHHarald J. Hoekstra
- 1 October 2009
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (28) , 4774-4780
Abstract
Purpose: Patients with melanoma with potentially resectable lymph node metastases require accurate staging to prevent unnecessary surgery. [18F]Fluorodeoxyglucose (FDG) positron emission tomography (PET) is attractive for this because melanoma typically is FDG avid. The aim of this prospective multicenter study was to perform a head-to-head comparison of FDG-PET and computed tomography (CT) in staging of patients with melanoma with palpable lymph node metastases in terms of diagnostic accuracy and impact on treatment. Patients and Methods: All consecutive patients with palpable, proven lymph node metastases of melanoma between mid 2003 and 2007 were prospectively included. The number/site of distant metastases detected with FDG-PET and CT were recorded. Histology/cytology or 6 months follow-up were the reference standard. Intended and performed treatment was recorded. Results: Distant metastases were suspected by FDG-PET in 32% of the 251 patients and by CT in 29% (P = .26). Upstaging was correct in 27% by FDG-PET and in 24% by CT (P = .18). FDG-PET detected more metastatic sites (133 v 112, P = .03), detecting significantly more bone and subcutaneous metastases. Treatment changed in 19% of patients; in 79% as a result of both scans, in 17% exclusively by FDG-PET, and in 4% exclusively by CT. In 34 patients (14%), FDG-PET had an additional value over spiral CT, and in 23 patients (9%), CT had additional value over FDG-PET. Conclusion: As a result of FDG-PET and CT, 27% of patients were upstaged, and treatment changed in one of five patients. FDG-PET and CT are equivalent in upstaging; however, FDG-PET detected more metastatic sites, especially bone and subcutaneous. FDG-PET and/or CT are indicated in the staging of patients with melanoma with palpable lymph node metastases.Keywords
This publication has 22 references indexed in Scilit:
- Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2007
- Level of Fluorodeoxyglucose Uptake Predicts Risk for Recurrence in Melanoma Patients Presenting With Lymph Node MetastasesAnnals of Surgical Oncology, 2006
- Diagnostic Performance of Whole Body Dual Modality 18F-FDG PET/CT Imaging for N- and M-Staging of Malignant Melanoma: Experience With 250 Consecutive PatientsJournal of Clinical Oncology, 2006
- Predictions of skin cancer incidence in the Netherlands up to 2015British Journal of Dermatology, 2005
- Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patientsAnnals of Surgical Oncology, 2002
- MRA in patients with cerebrovascular disease: Considerations of clinical effectivenessActa Radiologica, 2000
- Computed tomography in staging of patients with melanoma metastatic to the regional nodesAnnals of Surgical Oncology, 1997
- Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucoseBritish Journal of Dermatology, 1995
- Cancer Detection with Whole-Body PET Using 2-[18F]Fluoro-2-Deoxy-D-GlucoseJournal of Computer Assisted Tomography, 1993
- Note on the Sampling Error of the Difference Between Correlated Proportions or PercentagesPsychometrika, 1947